Government Partnerships And Better Payer Engagement: Janssen's Plan For Middle Eastern Growth
Executive Summary
Unexpected events like low oil prices and political unrest have made for a very challenging business environment in the Middle East and North Africa and led to a drop in growth. But Khaled Mansour, head of market access and external affairs EMEA Emerging Markets for Janssen, explains how with government partnerships the company plans to build up business from a new baseline.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.